Further studies are needed to better elucidate the role of YKL-40 as a CSF surrogate biomarker of neurodegeneration-related innate immunity activation in the pre-symptomatic/initial stages of AD continuum as well as in other neurodegenerative diseases, possibly in combination with established AD biomarkers. This evidence concerns the gene CHI3L1 and neurodegenerative disease.